Glucosamine-anchored doxorubicin-loaded targeted nano-niosomes: pharmacokinetic, toxicity and pharmacodynamic evaluation

Pawar, Smita K.; Shevalkar, Ganesh B.; Vavia, Pradeep R.

doi:10.3109/1061186x.2016.1154560

Cited by 38 publications

(15 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[52,53] Investigating the cytotoxicity of DOX on liver tissues showed similar levels of fibrotic tissue areas and congested central vein, yet the cytotoxic effects of systematic delivery of DOX on liver tissues have been reported by others. [54,55] The difference in our results could be explained by the high regenerative capacity of liver tissue which may contribute to the regeneration of any potential damage by day 28. Furthermore, the similarity between the Control group, I.V.…”

Section: Discussionmentioning

confidence: 58%

Local Doxorubicin Delivery via 3D‐Printed Porous Scaffolds Reduces Systemic Cytotoxicity and Breast Cancer Recurrence in Mice

Dang

Shafiee

Lahr

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

The concept of using macroscale porous scaffolds as local drug reservoirs to prevent cancer recurrence has received little attention. To extend the use of these scaffolds as drug delivery devices, the morphology needs to be optimized. Here, a porous scaffold that can work as efficient drug reservoirs is developed. A combination of additive manufacturing and salt leaching techniques to produce scaffolds of medical grade poly(ε‐caprolactone) that has macroscale pores of 300–500 µm and intrastrut microscale pores of 5–35 µm in size is used. The chemotherapeutic drug, doxorubicin (DOX), is loaded onto the porous scaffolds by soaking with the loading efficacy as high as 90%. The DOX‐loaded scaffolds display a biphasic monotonic drug release up to 28 d, and a dose‐dependent chemotherapeutic effect against breast cancer cells, MDA‐MB‐231. Compared to one‐time intravenous injection of 40 µg DOX, implantation of scaffolds containing only 2 or 8 µg of DOX after tumor removal in mice shows lower cardio‐cytotoxicity, reduced local cancer recurrence, and is correlated with a lower metastasis progression in lungs, liver, and spleen in 28 d of treatment. These bimodal scaffolds are thus promising in the development of scaffolds in breast cancer after tumor removal.

show abstract

Section: Discussionmentioning

confidence: 58%

Local Doxorubicin Delivery via 3D‐Printed Porous Scaffolds Reduces Systemic Cytotoxicity and Breast Cancer Recurrence in Mice

Dang

Shafiee

Lahr

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

show abstract

“…As alternative to liposomes, niosomes are widely-used drug delivery carriers because of their similar properties [65–67]. Niosomes are known for more than two decades in drug delivery applications [67–69].…”

Section: Liposomes or Lipid-based Nanoparticlesmentioning

confidence: 99%

“…Niosomes are known for more than two decades in drug delivery applications [67–69]. Niosomes are formed by the self-association of nonionic surfactants and cholesterol in an aqueous phase and have shown good physico-chemical stability and excellent loading efficiency of drugs of both hydrophilic and hydrophobic nature and also oligonucleotides [65, 66, 70]. The biodegradable, biocompatible and nontoxic nature of niosomes and their easy manipulation with targeting ligands makes them attractive drug delivery systems for cancer therapy [71].…”

Section: Liposomes or Lipid-based Nanoparticlesmentioning

confidence: 99%

Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems

Babu

Munshi

Ramesh

2017

Drug Development and Industrial Pharmacy

View full text Add to dashboard Cite

RNAi is emerging as a powerful approach in cancer treatment. siRNA is an important RNAi tool that can be designed to specifically silence the expression of genes involved in drug resistance and chemotherapeutic inactivity. Combining siRNA and other therapeutic agents can overcome the multi-drug resistance phenomenon by simultaneously silencing genes and enhancing chemotherapeutic activity. Moreover, the therapeutic efficiency of anti-cancer drugs can be significantly improved by additive or synergistic effects induced by siRNA and combined therapies. Co-delivery of these diverse anti-cancer agents, however, requires specially designed nanocarriers. This review highlights the recent trends in siRNA/anti-cancer drug co-delivery systems under the major categories of liposomes/lipid, polymeric, and inorganic nanoplatforms. The objective is to discuss the strategies for nanocarrier-based co-delivery systems using siRNA/anti-cancer drug combinations, emphasizing various siRNA targets that help overcome multi-drug resistance and enhance therapeutic efficiency.

show abstract

“…21,22 Most importantly, glucosamine (DA) as a "targeting group" has a good targeting effect for cancer cells/tissues. [23][24][25] Here, we report the research and development of a selfassembled DDS by targeting amphiphilic small molecules. The DDS nanoplatform conjugated the 2-glucosamine (2-DA), FITC/ICG, and PTX to an amphiphilic molecule and self-assembled these compounds in a nano-DDS.…”

Section: Introductionmentioning

confidence: 99%

<p>Targeted Prodrug-Based Self-Assembled Nanoparticles for Cancer Therapy</p>

Wang¹,

Fan²,

Zhu³

et al. 2020

IJN

View full text Add to dashboard Cite

Background: Targeted prodrug has various applications as drug formulation for tumor therapy. Therefore, amphoteric small-molecule prodrug combined with nanoscale characteristics for the self-assembly of the nano-drug delivery system (DDS) is a highly interesting research topic. Methods and Results: In this study, we developed a prodrug self-assembled nanoplatform, 2-glucosamine-fluorescein-5(6)-isothiocyanate-glutamic acid-paclitaxel (2DA-FITC-PTX NPs) by integration of targeted small molecule and nano-DDS with regular structure and perfect targeting ability. 2-glucosamine (DA) and paclitaxel were conjugated as the targeted ligand and anti-tumor chemotherapy drug by amino acid group. 2-DA molecular structure can enhance the targeting ability of prodrug-based 2DA-FITC-PTX NPs and prolong retention time, thereby reducing the toxicity of normal cell/tissue. The fluorescent dye FITC or near-infrared fluorescent dye ICG in prodrug-based DDS was attractive for in vivo optical imaging to study the behavior of 2DA-FITC-PTX NPs. In vitro and in vivo results proved that 2DA-FITC-PTX NPs exhibited excellent targeting ability, anticancer activity, and weak side effects. Conclusion: This work demonstrates a new combination of nanomaterials for chemotherapy and may promote prodrug-based DDS clinical applications in the future.

show abstract

Glucosamine-anchored doxorubicin-loaded targeted nano-niosomes: pharmacokinetic, toxicity and pharmacodynamic evaluation

Cited by 38 publications

References 41 publications

Local Doxorubicin Delivery via 3D‐Printed Porous Scaffolds Reduces Systemic Cytotoxicity and Breast Cancer Recurrence in Mice

Local Doxorubicin Delivery via 3D‐Printed Porous Scaffolds Reduces Systemic Cytotoxicity and Breast Cancer Recurrence in Mice

Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems

<p>Targeted Prodrug-Based Self-Assembled Nanoparticles for Cancer Therapy</p>

Contact Info

Product

Resources

About